HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST – Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.
Milestone Pharmaceuticals Stock Down 1.5 %
Shares of NASDAQ:MIST opened at $2.02 on Monday. Milestone Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $2.75. The company’s fifty day moving average is $1.96 and its two-hundred day moving average is $1.66. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The stock has a market capitalization of $107.73 million, a price-to-earnings ratio of -2.49 and a beta of 1.78.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.
Hedge Funds Weigh In On Milestone Pharmaceuticals
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Further Reading
- Five stocks we like better than Milestone Pharmaceuticals
- Top Stocks Investing in 5G Technology
- Sizing Up a New Opportunity for NVIDIA Investors
- How to Calculate Options Profits
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- 3 Tickers Leading a Meme Stock Revival
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.